To launch the commercialization of its innovative solution for the manufacturing of messenger RNA vaccines and therapies
Meylan, France, July 9, 2025 – Dillico announces the completion of a financing round with Angelor, the Fonds Régional Avenir Industrie of the Auvergne-Rhône-Alpes Region (advised by UI Investissement), the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, the GP Compas and Deepbright One funds, as well as private investors and family offices, including its historical investor Deeperly. Through this transaction, Dillico aims to launch the commercialization of its innovative solution for the manufacturing of messenger RNA vaccines and therapies.